Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

[Evaluation of the bern day treatment programme and its position in the psychiatric network].

Authors:
Thomas Reisch Martin Thommen Zsuzsanna Csontos Wolfgang Tschacher

Psychother Psychosom Med Psychol 2002 Feb;52(2):56-63

Universitäre Psychiatrische Dienste Bern, Direktion Sozial, und Gemeindepsychiatrie, Germany.

The Bern Day Treatment Programme offers cognitive-behavioural treatment to patients suffering from depression, eating disorders, anxiety disorders, and personality disorders. Treatment duration ranges from 12 to 20 weeks. Its concept is described in comparison to other similar institutions. To evaluate the programme the Beck Depression Inventory (BDI), the Symptom Check List (SCL-90-R), and the Change in Life Areas (VLB) were administered to 89 patients at admission and discharge. Their analyses revealed high symptom levels at admission and a significant improvement during treatment. Patients with personality disorders show less improvement in the VLB than patients without personality disorders. The results of the SCL-90-R indicate that the symptom levels at admission and the symptom reductions during treatment are similar to those of patients treated in inpatient units or in diagnostically specialised day treatment programmes. The Bern Day Treatment Programme seems to be feasible for highly impacted patients with non-psychotic disorders and might be a useful model for areas with low population density.

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-2002-20183DOI Listing
February 2002

Publication Analysis

Top Keywords

day treatment
16
bern day
12
personality disorders
12
treatment programme
12
treatment patients
12
patients personality
8
levels admission
8
treatment
8
symptom levels
8
patients
6
disorders
6
admission improvement
4
improvement treatment
4
high symptom
4
analyses revealed
4
disorders improvement
4
revealed high
4
patients admission
4
discharge analyses
4
admission discharge
4

Keyword Occurance

Similar Publications

Increasing incidence and prevalence of multiple sclerosis in the Greater Hobart cohort of Tasmania, Australia.

Authors:
Steve Simpson-Yap Roberts Atvars Leigh Blizzard Ingrid van der Mei Bruce V Taylor

J Neurol Neurosurg Psychiatry 2022 May 16. Epub 2022 May 16.

MS Flagship, Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.

Background: The Greater Hobart region (42.5°S) of Tasmania has consistently had the highest recorded prevalence and incidence rates of multiple sclerosis (MS) in Australia. We reassessed MS epidemiology in 2009-2019 and assessed longitudinal changes over 68 years. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT.

Authors:
María Queralt Salas Paola Charry Alexandra Pedraza Nuria Martínez-Cibrian María Teresa Solano Ariadna Domènech Maria Suárez-Lledó Meritxell Nomdedeu Joan Cid Miquel Lozano Noemi de-LLobet Jordi Arcarons Laura Rosiñol Gonzalo Gutiérrez-García Enric Carreras Jordi Esteve Álvaro Urbano-Ispizua Francesc Fernández-Avilés Montserrat Rovira Carmen Martínez

Transplant Cell Ther 2022 May 13. Epub 2022 May 13.

Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Fundació Josep Carreras Contra la Leucèmia; University of Barcelona.

Introduction: The use of PTCY for graft-versus-host disease (GHVD) prevention is becoming prevalent in the transplant community when HLA-identical sibling (MSD) and 10/10 HLA-matched (MUD) and 9/10 mismatched (MMUD) unrelated donors are selected for alloHSCT. However, reported evidence on outcomes from elderly receiving PTCY-containing GVHD prophylaxis remains limited.

Objectives: This study aims to compare the outcomes of PTCY-TK prophylaxis and conventional GVHD prophylaxis in patients aged >50 years undergoing peripheral blood alloHSCT from a single institution. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Network pharmacology analysis on mechanism of Jian Pi Qing Gan Yin decoction ameliorating high fat diet-induced non-alcoholic fatty liver disease and validated in vivo.

Authors:
Weiwei Liu Jingyu Shang Yinxiang Deng Xiuzhen Han Yugen Chen Shuangshuang Wang Ruwen Yang Fan Dong Hongtao Shang

J Ethnopharmacol 2022 May 13:115382. Epub 2022 May 13.

The Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, 210029, Jiangsu, China; Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, China. Electronic address:

Ethnopharmacological Relevance: Jian Pi Qing Gan Yin (JPQGY) has been used clinically to relieve non-alcoholic fatty liver disease (NAFLD) in China for decades; however, the underlying mechanisms of JPQGY remain unclear.

Aim Of The Study: We evaluated the effects and mechanisms of JPQGY and hepatic steatosis caused by the middle stage of 13-week-high-fat-diet-induced NAFLD in mice.

Materials And Methods: Different dosages of JPQGY (5. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Effect of trans-resveratrol on glutamate clearance and visual behaviour in rats with glutamate induced retinal injury.

Authors:
Tee Hann Yih Afiqq Aiman Abd Ghapor Renu Agarwal Norhafiza Razali Igor Iezhitsa Nafeeza Mohd Ismail

Exp Eye Res 2022 May 13:109104. Epub 2022 May 13.

School of Medicine, International Medical University, Bukit Jalil, Kuala Lumpur, Malaysia.

Glutamate-induced excitotoxic injury is widely described as a prominent pathophysiological mechanism in several neurodegenerative diseases including glaucoma. Glaucoma, the leading cause of irreversible blindness, is characterized by loss of retinal ganglion cells (RGC). Currently, the treatment focuses on lowering intraocular pressure (IOP) and no neuroprotective therapies are available. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes.

Authors:
Laura E Hawley Faith Prochaska Megan Stringer Charles R Goodlett Randall J Roper

Pharmacol Biochem Behav 2022 May 13:173404. Epub 2022 May 13.

Department of Biology, Indiana University-Purdue University Indianapolis, United States of America. Electronic address:

The neurotypical spatiotemporal patterns of gene expression are disrupted in Down syndrome (DS) by trisomy of human chromosome 21 (Hsa21), resulting in altered behavioral development and brain circuitry. The Ts65Dn DS mouse model exhibits similar phenotypes to individuals with DS due to three copies of approximately one-half of the genes found on Hsa21. Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1a (Dyrk1a), one of these triplicated genes, is an attractive target to normalize brain development due to its influence in cellular brain deficits seen in DS. Read More

View Article and Full-Text PDF
May 2022
Similar Publications
}
© 2022 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap